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Consider SSRIs as 
ﬁ rst-line therapy 
for adolescent 
depression 
  
Which drugs are most effective 
for moderate to severe 
depression in adolescents?
Fluoxetine: A valuable tool
Two studies—the Treatment for 
Adolescents with Depression Study 
(TADS)1 and the recently published 
Adolescent Depression, Antidepressants, 
and Psychotherapy Trial (ADAPT)2—both 
based on validated survey tools available 
in primary care, clearly demonstrate 
the effectiveness of SSRIs—particularly 
fl uoxetine—for alleviating depressive 
symptoms. 
 In my clinical practice, fl uoxetine is a 
valuable tool to rapidly improve depression 
and common comorbid conditions such as 
bulimia nervosa, anorexia nervosa, binge-
eating disorder not otherwise specifi ed, 
panic disorder, and obsessive-compulsive 
disorder. The recent ADAPT trial provides 
further convincing and consistent data that 
SSRI therapy should be considered fi rst-line 
therapy for adolescent depression. 
 Obviously, prudence mandates close 
follow-up of your teenage patients and 
thorough discussion of the risk of increased 
suicidality with both the patient and parent or 
guardian. 
Jason Crawford, MD, MPH
University of Nevada School of Medicine, Reno
Clinical commentary
Fluoxetine is the only selective serotonin- 
reuptake inhibitor (SSRI) approved by the 
US Food and Drug Administration (FDA) to 
treat depression in children 8 years of age 
and older; it also has the most favorable 
benefi t-to-risk profi le compared with 
placebo in trials lasting up to 12 weeks 
(strength of recommendation [SOR]: A, 
meta-analysis). Fluoxetine combined with 
cognitive behavioral therapy (CBT) 
is superior to fl uoxetine alone, CBT 
alone, or placebo (SOR: B, single well-
done randomized controlled trial [RCT]). 
Further research is needed to address 
the long-term effi cacy of fl uoxetine 
treatment. 
 Tricyclic antidepressants, citalopram, 
escitalopram, venlafaxine, and sertraline 
are minimally effective in treating 
depression in adolescents (SOR: A, 
meta-analysis). Head-to-head trials 
are needed to compare the effi cacy of 
antidepressants.
 (For information on the safety of 
antidepressants in adolescents, see the 
Clinical Inquiry on page 327.)
Evidence-based answer
❚ Evidence summary 
Fifteen well-designed trials have exam-
ined the effi cacy of antidepressants for 
treating major depressive disorder in 
youth. All reported the changes in total 
scores on standard depression scales: the 
Copy
right
® Dow
den H
ealth
 Med
ia  
For p
erson
al us
e onl
y
For mass reproduction, content licensing and permissions contact Dowden Health Media.
FAST TRACK
 VOL 57, NO 5 / MAY 2008 331www.jfponline.com
Children’s Depression Rating Scale-Re-
vised, Clinical Global Impressions, Ham-
ilton Rating Scale for Depression, or Kid-
die Schedule for Affective Disorders and 
Schizophrenia for School-Age Children. 
The TABLE summarizes the fi ndings for 
SSRIs and venlafaxine based on a meta-
analysis of the 15 trials.3 (For more on 
the characteristics and effi cacy of ven-
lafaxine and SSRIs in young people, 
see TABLE W1, available online at www.
jfponline.com.) 
The best bet: 
Fluoxetine plus CBT
The landmark Treatment for Adoles-
cents with Depression Study, which was 
included in the meta-analysis, comprised 
4 treatment arms: fl uoxetine alone, 
CBT  alone, fl uoxetine with CBT, and 
placebo. Only the combination therapy 
group showed a statistically signifi cant 
improvement compared with placebo in 
the primary outcome (improved Chil-
dren’s Depression Rating Scale-Revised). 
Improvement in the Clinical Global Im-
pressions score, a subjective measure, 
was statistically signifi cant in 71% of pa-
tients receiving combination therapy and 
60.6% of those treated with fl uoxetine 
compared with placebo (34.8%) or CBT 
alone (43.2%).1 
Two RCTs showed that sertraline was 
slightly, but statistically signifi cantly, bet-
ter than placebo when the 2 identically 
designed trials were combined.4 Pooled 
results of 3 RCTs demonstrated that par-
oxetine was no better than placebo.3 Two 
RCTs of citalopram and 1 RCT of esci-
talopram showed marginally signifi cant 
benefi t over placebo only when pooled.3 
A post hoc subgroup analysis of 2 com-
bined RCTs comparing extended-release 
venlafaxine with placebo showed modest, 
statistically signifi cant improvement in 
depressive symptoms in adolescents, but 
not children.5 A 2007 Cochrane review 
supports the use of SSRIs to treat major 
depressive disorder in adolescents, report-
ing effi cacy as 1.28 times that of placebo 
(95% confi dence interval, 1.17-1.41).6
Quality of available clinical evidence is 
limited. Statistical signifi cance was demon-
strated in meta-analyses only when data 
from smaller trials were combined.  Fluox-
etine was the only antidepressant studied 
in nonindustry-sponsored trials for major 
depressive disorder in adolescents. More-
over, results are not often reported sepa-
rately for children (5-12 years of age) and 
adolescents (12-18 years of age). 
Side effects are an issue 
for tricyclics
A 2002 Cochrane meta-analysis reported 
marginal evidence to support using tri-
cyclic antidepressants for treating ado-
lescents. However, these drugs have sig-
nifi cantly more side effects than placebo.7 
No placebo-controlled RCTs of bupropi-
on, duloxetine, mirtazapine, or St. John’s 
wort for treating major depressive disor-
der in adolescents were identifi ed.
Recommendations 
A 1998 practice parameter published by 
The American Academy of Child and 
Adolescent Psychiatry (AACAP) strongly 
favors psychotherapy alone or in com-
bination with medication. The guide-
line recommends treatment throughout 
the acute and continuation phase of ill-
ness—at least 6 months—with possible 
active treatment during the maintenance 
phase (which begins after 6 months to 
1 year without symptoms and may ex-
tend indefi nitely). AACAP advocates us-
ing SSRIs as fi rst-line therapy without 
endorsing a specifi c medication.8
The Society for Adolescent Medicine 
supports pharmacotherapy for depressed 
adolescents, stating that “data supporting 
the effectiveness of selective serotonin- 
reuptake inhibitors for adolescents with 
major depressive disorder, particularly for 
fl uoxetine, is compelling.”9 Similarly, the 
American College of Neuropsychophar-
macology notes that the risk-to-benefi t 
ratio favors drug therapy for moderate to 
severe depression in adolescents and rec-
ommends fl uoxetine as an effective treat-
ment for major depression in youth; RCTs 
Fluoxetine 
combined with 
cognitive 
behavioral therapy 
is superior 
to ﬂ uoxetine alone
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comparing other SSRIs with fl uoxetine are 
needed to establish the effi cacy of these 
drugs.10 ■
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Efﬁ cacy of SSRIs and venlafaxine in young people
DRUG
ABSOLUTE RISK 
REDUCTION %* (95% CI) NNT (95% CI)
Citalopram/escitalopram† 8 (1 to 16) 13 (7 to 200)
Fluoxetine† ‡ 20 (11 to 29) 6 (4 to 10)
Sertraline§ 10 (0 to 20) 10 (6 to 500)
Paroxetine† 5 (-3 to 13) NA
Venlafaxine‡ 11 (1 to 21) 10 (5 to 112)
CI, confi dence interval; NNT, number needed to treat; SSRIs, selective serotonin-reuptake inhibitors.
* Absolute risk reduction is the risk difference when comparing agent to placebo using differences in measures 
of standardized depression scales before and after therapy (Hamilton Rating Scale for Depression, Clinical Global 
Impressions, Children’s Depression Rating Scale-Revised, or Kiddie Schedule for Affective Disorders and 
Schizophrenia for School-Age Children).
† Estimates from pooled data.
‡ NNT represents average of NNT of individual trials pooled.
§  2 randomized controlled trials combined.
Source: Bridge JA et al.3
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